Constellation, the first SaaS enterprise technology platform that enables top companies and Fortune 500 companies in highly regulated industries to build, deploy and manage digital innovation at scale, today announced a major investment from Newlight Partners LP (“ Newlight”), a trading company.
This investment comes as Constellation continues to grow in its key areas of automotive and commercial in 2022, as well as expanding into attractive new industries, such as pharmaceuticals, where its expertise supports digital marketing for drugmakers, including Biohaven Pharmaceuticals ( acquired by Pfizer in 2022 for $11.8 billion), Alnylam Pharmaceuticals, and Sanofi, among others. The proceeds from Newlight’s investment will be used to support the rapid growth of Constellation’s technology in the automotive, pharmaceutical, and financial industries, as well as to develop its leading, global manufacturing operations, such as the Volkswagen Group and Jaguar Land Rover, among others. .
“Constellation was founded in 2016 as a way to help car companies and retailers to reach customers through digital advertising. Since then, thanks to the success and power of our platform, we have expanded our work to improve the marketing strategy to help different companies, especially who are working in highly regulated industries,” said Diana Lee, Co-Founder and CEO of Constellation. . “I am excited to partner with Newlight as we enter the next chapter and expand into new industries, including the highly attractive pharmaceutical sector, and make acquisitions to further the growth of Constellation.”
Through this investment from Newlight, Constellation will strive to continue to deliver positive results for its customers as it works to meet the demand for its technology in new industries. Constellation’s differentiated platform provides SaaS/tech-enabled marketing and omnichannel creative deployment that effectively reaches customers and drives sales and compliance with complex regulatory requirements by seamlessly integrating into the client’s existing infrastructure and leveraging a proprietary compliance engine. To that end, Constellation recently launched its Verticalized Modular Content Assembler technology, which can create thousands of targeted, responsive, seamless, and customizable content in industry-leading seconds.
“We are delighted to partner with Constellation, whose platform has become the standard solution for marketing managers in the most complex and regulated industries,” said Jeremiah Liao, Managing Director at Newlight. “We believe Constellation’s ability to innovate and grow in industries around the world is a great opportunity, and we look forward to working with Diana and her talented team to further their ability to grow physically and professionally.”
“Constellation exemplifies Newlight’s thematic approach and the type of business we want to invest in – a sustainable company with exceptional leadership, a unique customer focus, and opportunities for growth,” added Adam Stulberger, Partner at Newlight. “As Constellation’s first partner, we are excited to support the business through its next phase of growth as it continues to innovate.”
In addition to the capital investment, Constellation announced two new executive hires to drive the company’s continued growth in the pharmaceutical industry. Ex-Pfizer and ConcertAI executive Melissa Gunn has joined as SVP of Customer Success and Strategic Partnerships, and Derek Wiggins, who previously led the Americas at Takumi, has joined as SVP of Business Development. Constellation also brought on former MediaMath CEO and ad tech pioneer Joe Zawadzki as a consultant.
Discover the latest marketing tools and techniques Martech News. Follow us MTC Podcast for new components and updates.